209 related articles for article (PubMed ID: 28280146)
1. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction.
Andersson DP; Trolle Lagerros Y; Grotta A; Bellocco R; Lehtihet M; Holzmann MJ
Heart; 2017 Aug; 103(16):1264-1270. PubMed ID: 28280146
[TBL] [Abstract][Full Text] [Related]
2. Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease.
Andersson DP; Landucci L; Lagerros YT; Grotta A; Bellocco R; Lehtihet M; Holzmann MJ
J Am Coll Cardiol; 2021 Mar; 77(12):1535-1550. PubMed ID: 33766260
[TBL] [Abstract][Full Text] [Related]
3. Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors.
Trolle Lagerros Y; Grotta A; Freyland S; Grannas D; Andersson DP
J Am Coll Cardiol; 2024 Jan; 83(3):417-426. PubMed ID: 38233015
[TBL] [Abstract][Full Text] [Related]
4. Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data.
Kloner RA; Stanek E; Crowe CL; Singhal M; Pepe RS; Bradsher J; Rosen RC
J Sex Med; 2023 Jan; 20(1):38-48. PubMed ID: 36897243
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality.
Anderson SG; Hutchings DC; Woodward M; Rahimi K; Rutter MK; Kirby M; Hackett G; Trafford AW; Heald AH
Heart; 2016 Nov; 102(21):1750-1756. PubMed ID: 27465053
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors.
Garrido Abad P; Sinués Ojas B; Martínez Blázquez L; Conde Caturla P; Fernández Arjona M
Actas Urol Esp; 2015 Dec; 39(10):635-40. PubMed ID: 26049734
[TBL] [Abstract][Full Text] [Related]
7. Recurrent myocardial infarction after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Kikkert WJ; Hoebers LP; Damman P; Lieve KV; Claessen BE; Vis MM; Baan J; Koch KT; de Winter RJ; Piek JJ; Tijssen JG; Henriques JP
Am J Cardiol; 2014 Jan; 113(2):229-35. PubMed ID: 24188893
[TBL] [Abstract][Full Text] [Related]
8. Sex differences in investigations and outcomes among patients with type 2 myocardial infarction.
Kimenai DM; Lindahl B; Chapman AR; Baron T; Gard A; Wereski R; Meex SJR; Jernberg T; Mills NL; Eggers KM
Heart; 2021 Sep; 107(18):1480-1486. PubMed ID: 33879450
[TBL] [Abstract][Full Text] [Related]
9. The association of tadalafil exposure with lower rates of major adverse cardiovascular events and mortality in a general population of men with erectile dysfunction.
Kloner RA; Stanek E; Desai K; Crowe CL; Paige Ball K; Haynes A; Rosen RC
Clin Cardiol; 2024 Feb; 47(2):e24234. PubMed ID: 38377018
[TBL] [Abstract][Full Text] [Related]
10. Relationship between treatment of erectile dysfunction and future risk of cardiovascular disease: A nationwide cohort study.
Vestergaard N; Søgaard P; Torp-Pedersen C; Aasbjerg K
Eur J Prev Cardiol; 2017 Sep; 24(14):1498-1505. PubMed ID: 28656785
[TBL] [Abstract][Full Text] [Related]
11. [Sex, erectile dysfunction, and the heart: a growing problem].
Görge G; Flüchter S; Kirstein M; Kunz T
Herz; 2003 Jun; 28(4):284-90. PubMed ID: 12825143
[TBL] [Abstract][Full Text] [Related]
12. Alprostadil for the treatment of impotence.
Hanchanale V; Eardley I
Expert Opin Pharmacother; 2014 Feb; 15(3):421-8. PubMed ID: 24369066
[TBL] [Abstract][Full Text] [Related]
13. Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative.
Ferreira JP; Duarte K; Pfeffer MA; McMurray JJV; Pitt B; Dickstein K; Zannad F; Rossignol P;
Eur J Heart Fail; 2018 Feb; 20(2):323-331. PubMed ID: 29314455
[TBL] [Abstract][Full Text] [Related]
14. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
[TBL] [Abstract][Full Text] [Related]
15. Short and long-term survival after primary percutaneous coronary intervention in young patients with ST-elevation myocardial infarction.
Waziri H; Jørgensen E; Kelbæk H; Stagmo M; Pedersen F; Lagerqvist B; James S; Køber L; Wachtell K
Int J Cardiol; 2016 Jan; 203():697-701. PubMed ID: 26583845
[TBL] [Abstract][Full Text] [Related]
16. Relation of Testosterone Normalization to Mortality and Myocardial Infarction in Men With Previous Myocardial Infarction.
Oni OA; Dehkordi SHH; Jazayeri MA; Sharma R; Sharma M; Masoomi R; Sharma R; Gupta K; Barua RS
Am J Cardiol; 2019 Oct; 124(8):1171-1178. PubMed ID: 31409450
[TBL] [Abstract][Full Text] [Related]
17. Relation between preoperative renal dysfunction and cardiovascular events (stroke, myocardial infarction, or heart failure or death) within three months of isolated coronary artery bypass grafting.
Holzmann MJ; Sartipy U
Am J Cardiol; 2013 Nov; 112(9):1342-6. PubMed ID: 23870631
[TBL] [Abstract][Full Text] [Related]
18. ERECTILE DYSFUNCTION AS A PREDICTOR OF CARDIOVASCULAR DISEASE.
Janjgava S; Doliashvili T
Georgian Med News; 2016 Dec; (261):36-41. PubMed ID: 28132040
[TBL] [Abstract][Full Text] [Related]
19. Risk and benefit of dual antiplatelet treatment among non-revascularized myocardial infarction patients in different age groups.
Juul N; Gislason G; Olesen JB; Lamberts M; Hansen ML; Karasoy D; Christiansen CB; Torp-Pedersen C; Sorensen R
Eur Heart J Acute Cardiovasc Care; 2017 Sep; 6(6):511-521. PubMed ID: 24936092
[TBL] [Abstract][Full Text] [Related]
20. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors.
Gazzaruso C; Solerte SB; Pujia A; Coppola A; Vezzoli M; Salvucci F; Valenti C; Giustina A; Garzaniti A
J Am Coll Cardiol; 2008 May; 51(21):2040-4. PubMed ID: 18498958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
